腎細胞癌におけるBasic Fibroblast Growth Factorの腫瘍マーカーとしての有用性の研究

Abstract

Serum levels of basic fibroblast growth factor (FGF) by enzyme immunoassay in patients with various urogenital tumors were examined in the present investigation. The incidence of renal cell carcinoma with increased serum levels of basic FGF (28 of 52, 53.8%) was significantly higher than those of any other urogenital tumors such as bladder cancer (6 of 26, 23.1%), testicular tumor (0 of 12, 0%) and prostatic cancer (2 of 7, 28.6%). Increased serum basic FGF was detected more frequently in patients with advanced renal cell carcinoma, stage pT3, grade G2. Analysis of histopathological pattern indicated that renal cell carcinoma with a solid or tubular component had a higher tendency of increased serum basic FGF. However, no significant difference was seen in the incidence of patients with increased serum basic FGF between c1ear cell subtype group (18 of 36, 50.0%) and granular cell subtype group (4 of 6, 66.7%). Thus, increase of serum basic FGF does not appear to depend on the cell type. Serum basic FGF may be produced and secreted from tumor tissue with pathologically high grade malignancy. Forty-five resected renal cell carcinomas were divided into two groups based on the maximum diameter of the primary tumor: ≧ 5cm and < 5cm; there was not a significant difference between these two groups. Five of 8 patients with renal cell carcinoma who underwent selective renal venous sampling before operation showed increased serum basic FGF in the renal vein from the affected kidney. After resection of the affected kidney, serum basic FGF disappeared within 2 weeks. However, residual huge tumor or postoperative disease prolonged the increased levels of serum basic FGF in 2 patients, indicating that serum basic FGF is produced from and secreted by tumor tissue itself. These findings may suggest that serum basic FGF can be a useful tumor marker in patients with renal cell carcinoma.